Cancer BiologybioRxivPreprint
Therapy resistance in AML is mediated by cytoplasmic sequestration of the transcriptional repressor IRF2BP2
Mark Jordan Althoff, Mohd Minhajuddin, Brett M. Stevens…·Craig T. Jordan
This study identifies IRF2BP2 cytoplasmic sequestration by MCL1 as a mechanism driving venetoclax and azacitidine resistance in AML through ACSL1 derepression.
DOI 10.1101/2025.05.22.655396